drugset / Trial / NCT01887353

The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure

NCT01887353

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy of ranolazine in the prevention of recurrent atrial fibrillation in post-cardioversion patients with heart failure and preserved ejection fraction.

Timeline

Start
2013-06
Primary completion
2014-02
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ranolazine Small molecule 1000 mg